We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

4 hedge funds and large institutions have $284K invested in Phio Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

20% less funds holding

Funds holding: 5 → 4 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

63% less capital invested

Capital invested by funds: $758K → $284K (-$474K)

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
+$43.2K
2
TSS
Two Sigma Securities
New York
+$43.2K
3
VKH
Virtu KCG Holdings
New York
+$43.2K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$284K
2
Renaissance Technologies
Renaissance Technologies
New York
-$164K
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$153K
4
Goldman Sachs
Goldman Sachs
New York
-$41K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$75K – – –
VKH
2
Virtu KCG Holdings
New York
$47K +$43.2K +1 New
Bank of New York Mellon
3
Bank of New York Mellon
New York
$42K +$43.2K +1 New
TSS
4
Two Sigma Securities
New York
$39K +$43.2K +1 New
Geode Capital Management
5
Geode Capital Management
Massachusetts
$21K – – –
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$14K – – –
BlackRock
7
BlackRock
New York
$11K – – –
RJFSA
8
Raymond James Financial Services Advisors
Florida
$10K – – –
UBS Group
9
UBS Group
Switzerland
$10K – – –
Northern Trust
10
Northern Trust
Illinois
$9K – – –
Wells Fargo
11
Wells Fargo
California
$3K – – –
PAM
12
Panagora Asset Management
Massachusetts
$2K – – –
Bank of America
13
Bank of America
North Carolina
$1K – – –
SM
14
Sabby Management
Florida
– -$284K -7 Closed
Hudson Bay Capital Management
15
Hudson Bay Capital Management
Connecticut
– -$153K -4 Closed
Renaissance Technologies
16
Renaissance Technologies
New York
– -$164K -4 Closed
Goldman Sachs
17
Goldman Sachs
New York
– -$41K -1 Closed

PHIO Hedge Fund Activity: Q1 2017 in Review

4 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q1 2017, worth a combined $284K — down 63% from $758K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of PHIO and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Bank of New York Mellon, opening a new position worth an estimated $43.2K. The largest seller was Sabby Management, exiting entirely with an estimated $284K sold.

  • 4 institutional investors held Phio Pharmaceuticals (PHIO) as of Q1 2017, down from 5 in Q4 2016.
  • Funds reported $284K of Phio Pharmaceuticals stock for Q1 2017, down 63% quarter-over-quarter.
  • 3 funds opened new Phio Pharmaceuticals positions in Q1 2017 and 4 closed out, a net change of -1 holder.
  • The largest Phio Pharmaceuticals buyer in Q1 2017 was Bank of New York Mellon, an estimated $43.2K added.
  • The largest Phio Pharmaceuticals seller in Q1 2017 was Sabby Management, an estimated $284K sold.

Based on aggregated 13F filings for Q1 2017.